dek-can fusion protein
DEK-CAN fusion protein (342-357) is a synthetic peptide fragment corresponding to amino acids 342 to 357 of the DEK-CAN oncoprotein, a chimeric molecule resulting from the t(6;9)(p23;q34) chromosomal translocation commonly identified in certain subtypes of acute myeloid leukemia (AML). This fusion protein brings together functional domains of the DEK and CAN (also known as NUP214) proteins, both of which play significant roles in chromatin remodeling and nucleocytoplasmic transport. The resulting hybrid molecule is a key focus in cancer biology due to its involvement in the dysregulation of gene expression, cellular proliferation, and leukemogenesis. As a research reagent, the DEK-CAN fusion protein (342-357) peptide fragment serves as a valuable tool for dissecting the molecular mechanisms underlying fusion-driven malignancies and for developing targeted investigative assays.
Cancer biology research: The DEK-CAN fusion peptide is widely utilized in studies aiming to elucidate the oncogenic mechanisms associated with the DEK-CAN translocation event. By providing a defined region of the fusion protein, researchers can investigate the specific biochemical interactions, post-translational modifications, and structural features that contribute to aberrant cellular processes in leukemia. This peptide fragment enables detailed mapping of protein-protein interactions, facilitating the identification of critical binding partners and downstream signaling pathways implicated in malignant transformation.
Antibody generation and assay development: The synthetic peptide corresponding to the DEK-CAN fusion junction is commonly employed as an immunogen for the production of highly specific monoclonal and polyclonal antibodies. These antibodies are instrumental for the selective detection of the fusion protein in cell lysates, tissue samples, and various experimental models. Furthermore, the peptide serves as a standard or positive control in immunoassays, such as Western blotting or ELISA, ensuring the reliable and accurate measurement of DEK-CAN expression in research settings.
Epitope mapping and structural studies: The defined amino acid sequence of the DEK-CAN fusion protein (342-357) fragment provides a precise substrate for epitope mapping experiments. By using this peptide in binding assays or structural analyses, researchers can delineate antibody recognition sites, characterize conformational epitopes, and gain insights into the three-dimensional organization of the fusion region. Such studies are critical for understanding how structural alterations in the fusion protein affect its function and interactions within the cellular environment.
Peptide-based screening and inhibitor design: The DEK-CAN fusion peptide is also applied in high-throughput screening platforms to identify small molecules, peptides, or other agents that can disrupt specific domains or interactions unique to the fusion protein. By employing this fragment as a target in binding or inhibition assays, investigators can prioritize compounds with potential for selective interference with oncogenic fusion activity. This approach supports the early-phase validation of candidate molecules for further research in anti-cancer strategy development.
Functional analysis in cellular models: Introducing the DEK-CAN (342-357) peptide fragment into cultured cells or cell-free systems enables the study of its direct biological effects, such as modulation of transcriptional regulation, influence on chromatin architecture, or alteration of nucleocytoplasmic transport. Such functional assays provide mechanistic insights into how this region of the fusion protein contributes to cellular phenotypes associated with leukemogenesis, supporting the development of new hypotheses and experimental models in cancer research.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More